具有PD-L1特征表达的肿瘤细胞组用于抗癌药物和免疫检查点抑制剂相互作用的临床前研究

IF 0.7 Q4 CHEMISTRY, MULTIDISCIPLINARY Moscow University Chemistry Bulletin Pub Date : 2023-03-25 DOI:10.3103/S0027131422070045

T. A. Bogush, A. A. Basharina, A. M. Scherbakov, K. I. Chandran, A. L. Mikhailova, I. P. Romanov, E. A. Bogush, V. S. Kosorukov

{"title":"具有PD-L1特征表达的肿瘤细胞组用于抗癌药物和免疫检查点抑制剂相互作用的临床前研究","authors":"T. A. Bogush, A. A. Basharina, A. M. Scherbakov, K. I. Chandran, A. L. Mikhailova, I. P. Romanov, E. A. Bogush, V. S. Kosorukov","doi":"10.3103/S0027131422070045","DOIUrl":null,"url":null,"abstract":"<p>PD-L1 (Programmed death-ligand 1), a membrane protein of the immunoglobulin superfamily, is one of the targets for cancer immunotherapy. A panel of 14 cancer cell cultures with a different constitutive PD-L1 expression level is formed and characterized. The panel is recommended for preclinical studies of a cytostatic drug effect on PD-L1 expression and for predicting the efficacy of their combination with immune checkpoint inhibitors.</p>","PeriodicalId":709,"journal":{"name":"Moscow University Chemistry Bulletin","volume":"77 1","pages":"S19 - S24"},"PeriodicalIF":0.7000,"publicationDate":"2023-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumor Cell Panel with Characterized Expression of PD-L1 for Preclinical Studies of Anticancer Drugs and Immune Checkpoint Inhibitors’ Interaction\",\"authors\":\"T. A. Bogush, A. A. Basharina, A. M. Scherbakov, K. I. Chandran, A. L. Mikhailova, I. P. Romanov, E. A. Bogush, V. S. Kosorukov\",\"doi\":\"10.3103/S0027131422070045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>PD-L1 (Programmed death-ligand 1), a membrane protein of the immunoglobulin superfamily, is one of the targets for cancer immunotherapy. A panel of 14 cancer cell cultures with a different constitutive PD-L1 expression level is formed and characterized. The panel is recommended for preclinical studies of a cytostatic drug effect on PD-L1 expression and for predicting the efficacy of their combination with immune checkpoint inhibitors.</p>\",\"PeriodicalId\":709,\"journal\":{\"name\":\"Moscow University Chemistry Bulletin\",\"volume\":\"77 1\",\"pages\":\"S19 - S24\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Moscow University Chemistry Bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.3103/S0027131422070045\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Moscow University Chemistry Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.3103/S0027131422070045","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

摘要

PD-L1(程序性死亡配体1)是免疫球蛋白超家族的一种膜蛋白，是癌症免疫治疗的靶点之一。14个具有不同组成性PD-L1表达水平的癌细胞培养小组形成并表征。该小组被推荐用于细胞抑制药物对PD-L1表达的影响的临床前研究，以及预测它们与免疫检查点抑制剂联合使用的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

摘要图片

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Tumor Cell Panel with Characterized Expression of PD-L1 for Preclinical Studies of Anticancer Drugs and Immune Checkpoint Inhibitors’ Interaction

PD-L1 (Programmed death-ligand 1), a membrane protein of the immunoglobulin superfamily, is one of the targets for cancer immunotherapy. A panel of 14 cancer cell cultures with a different constitutive PD-L1 expression level is formed and characterized. The panel is recommended for preclinical studies of a cytostatic drug effect on PD-L1 expression and for predicting the efficacy of their combination with immune checkpoint inhibitors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Moscow University Chemistry Bulletin CHEMISTRY, MULTIDISCIPLINARY-

CiteScore

1.30

自引率

14.30%

发文量

期刊介绍： Moscow University Chemistry Bulletin is a journal that publishes review articles, original research articles, and short communications on various areas of basic and applied research in chemistry, including medical chemistry and pharmacology.